FDA approves new drug application for Pliaglis

Article

The Food and Drug Administration has approved a supplemental new drug application for Pliaglis (lidocaine 7 percent, tetracaine 7 percent), a topical anesthetic cream.

Related Videos
Related Content

Real-World Insights: Systemic Therapies in Moderate to Severe Atopic Dermatitis Patients

October 3rd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

SARS-CoV-2 Associated With Increased Incidence of Psoriasis

October 3rd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Discovering Last Month's Psoriasis Spotlight

October 3rd 2023

Jeremy Brauer, MD, Publishes Men’s Aesthetics Textbook

October 2nd 2023

Real-World Insights: Systemic Therapies in Moderate to Severe Atopic Dermatitis Patients

October 3rd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

SARS-CoV-2 Associated With Increased Incidence of Psoriasis

October 3rd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Discovering Last Month's Psoriasis Spotlight

October 3rd 2023

Jeremy Brauer, MD, Publishes Men’s Aesthetics Textbook

October 2nd 2023

Real-World Insights: Systemic Therapies in Moderate to Severe Atopic Dermatitis Patients

October 3rd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

SARS-CoV-2 Associated With Increased Incidence of Psoriasis

October 3rd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Discovering Last Month's Psoriasis Spotlight

October 3rd 2023

Jeremy Brauer, MD, Publishes Men’s Aesthetics Textbook

October 2nd 2023
© 2023 MJH Life Sciences

All rights reserved.